Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-IL-20 (NNC109-0012) in Rheumatoid Arthritis
NCT01282255Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2011
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing NNC109-0012 with Placebo (2 arms). Primary endpoint: Change in Disease Activity Score 28-CRP at 12 weeks. Started Feb 2011; status: completed.
02
Drugs
fletikumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01282255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01282255.